Close Menu
November 03, 2020
Sponsored by
Agilent

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Genome Webinar

Lead Scientist, Molecular Profiling, NEO New Oncology

Global Product Manager, Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers. While conventional technologies, such as FISH and PCR, allow accurate low-throughput detection (e.g., EML4-ALK fusion), next-generation sequencing-based approaches enable comprehensive and simultaneous identification of various alterations (single nucleotide variants, insertions/deletions, fusions, copy number alterations) and genomic signatures (microsatellite instability, tumor mutational burden).

Compared to conventional technologies, NGS-based approaches overcome the challenge of limited materials and reduce the turnaround time. However, further improvements are still needed due to the complex structure of the genome, including repetitive regions and high GC/AT content.

In this webinar, Dr. Judith Müller-Eisert of NEO New Oncology will discuss a collaboration with Agilent Technologies to develop several hybrid capture-based assays for various tumor entities using the SureSelect XT HS2 chemistry. She will share details of the kit’s performance and discuss its use as a powerful tool for cancer profiling.

For Research Use Only. Not for use in diagnostic procedures.

Sponsored by
Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.